Pharma’s increasing ability to address unmet need in plaque psoriasis with a range of different approaches is helping the market to rise at a compound annual growth rate (CAGR) of 4.1%.
GlobalData’s report, titled Plaque Psoriasis: Global Drug Forecast and Market Analysis to 2027, predicts growth from $16.2 billion in 2017 to $24.2 billion in 2027 across the seven major markets of the USA, Japan, France, Italy, Germany, Spain and the UK.
"The most neglected segment is the mild severity"
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze